Concord Biotech Limited (CONCORDBIO)
Healthcare | Biotechnology
₹2120.55
-1.85%
Margin Metrics
| Gross Margin | 75.8% |
| Operating Margin | 38.7% |
| Net Margin | 30.9% |
Return Metrics
| Return on Equity (ROE) | 0.0% |
| Return on Assets (ROA) | 18.1% |
| Return on Invested Capital (ROIC) | 2975.2% |
Profitability Analysis Score: 80/100
Profitability Score: 80/100
Key Performance Indicators:
- Excellent cost management with gross margin above 40%
- Superior operational efficiency with margin above 25%
- Excellent profitability with net margin above 20%
- Excellent capital efficiency with ROIC above 20%
Recommendation
Exceptional Profitability - Company demonstrates superior financial performance and efficiency
Detailed Analysis
Margin Analysis: Gross margin of 75.8% indicates exceptional cost management.
Operational Efficiency: Operating margin of 38.7% shows excellent operational control.
Bottom Line: Net margin of 30.9% demonstrates superior overall profitability.
Risk Assessment Guide
- Score 80-100: Superior profitability with strong competitive advantages
- Score 60-79: Healthy profitability with good market position
- Score 40-59: Average profitability with improvement opportunities
- Score Below 40: Weak profitability requiring strategic intervention
Key Metrics
- Return on Equity: 0.0%
- Return on Invested Capital: 2975.2%
- Return on Assets: 18.1%
Last Updated: 23-Jan-2025 06:51 AM